These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 2908013)
1. [Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment]. Guastavino E; Litwin NH; Heffes Nahmod L; Licastro R Acta Gastroenterol Latinoam; 1988; 18(2):107-13. PubMed ID: 2908013 [TBL] [Abstract][Full Text] [Related]
2. [Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration]. Klugmann HJ; Giehler B; Lohmann D; Schiedewitz W Gastroenterol J; 1990; 49(4):160-4. PubMed ID: 1970478 [TBL] [Abstract][Full Text] [Related]
3. [Determination of sulfapyridine levels in serum--a possibility for the control of dose related therapy with sulfasalazine]. Eitner K; Reinicke C; Hippius M Dtsch Z Verdau Stoffwechselkr; 1984; 44(6):282-8. PubMed ID: 6151895 [TBL] [Abstract][Full Text] [Related]
4. Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and its metabolites in B6C3F1 mice. Zheng W; Winter SM; Mayersohn M; Bishop JB; Sipes IG Drug Metab Dispos; 1993; 21(6):1091-7. PubMed ID: 7905389 [TBL] [Abstract][Full Text] [Related]
5. Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine. Goldstein PD; Alpers DH; Keating JP J Pediatr; 1979 Oct; 95(4):638-40. PubMed ID: 39125 [TBL] [Abstract][Full Text] [Related]
6. [Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)]. Eitner K; Hippius M; Reinicke C Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):14-9. PubMed ID: 6122556 [TBL] [Abstract][Full Text] [Related]
7. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine. Kimura I; Kumamoto T; Matsuda A; Kataoka M; Kokuba Y Arzneimittelforschung; 1998 Oct; 48(10):1007-11. PubMed ID: 9825118 [TBL] [Abstract][Full Text] [Related]
8. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats. Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431 [TBL] [Abstract][Full Text] [Related]
9. Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings. Bates TR; Blumenthal HP; Pieniaszek HJ Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):183-9. PubMed ID: 9675 [TBL] [Abstract][Full Text] [Related]
10. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine. Kimura I; Kawasaki M; Matsuda A; Kataoka M; Kokurba Y Arzneimittelforschung; 1998 Dec; 48(12):1163-7. PubMed ID: 9893931 [TBL] [Abstract][Full Text] [Related]
11. Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk. Berlin CM; Yaffe SJ Dev Pharmacol Ther; 1980; 1(1):31-9. PubMed ID: 6108198 [TBL] [Abstract][Full Text] [Related]
12. Sulfapyridine appearance in plasma after salicylazosulfapyridine. Another simple measure of intestinal transit. Kellow JE; Borody TJ; Phillips SF; Haddad AC; Brown ML Gastroenterology; 1986 Aug; 91(2):396-400. PubMed ID: 2873075 [TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis. Allgayer H; Kruis W; Eisenburg J; Paumgartner G Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549 [TBL] [Abstract][Full Text] [Related]
14. Hemolysis during salicylazosulfapyridine therapy. van Hees PA; van Elferen LW; van Rossum JM; van Tongeren JH Am J Gastroenterol; 1978 Nov; 70(5):501-5. PubMed ID: 33552 [TBL] [Abstract][Full Text] [Related]
15. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age. Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489 [TBL] [Abstract][Full Text] [Related]
16. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis. Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518 [TBL] [Abstract][Full Text] [Related]
17. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Esbjörner E; Järnerot G; Wranne L Acta Paediatr Scand; 1987 Jan; 76(1):137-42. PubMed ID: 2882643 [TBL] [Abstract][Full Text] [Related]
18. Cholestyramine-induced inhibition of salicylazosulfapyridine (sulfasalazine) metabolism by rat intestinal microflora. Pieniaszek HJ; Bates TR J Pharmacol Exp Ther; 1976 Jul; 198(1):240-5. PubMed ID: 6792 [TBL] [Abstract][Full Text] [Related]
19. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases. Rahav G; Zylber-Katz E; Rachmilewitz D; Levy M Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894 [TBL] [Abstract][Full Text] [Related]
20. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Järnerot G; Into-Malmberg MB; Esbjörner E Scand J Gastroenterol; 1981; 16(5):693-7. PubMed ID: 6119765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]